Drug Trial Radar · NCT05623020
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,060
Planned (sponsor's estimate)
Start
Nov 10, 2022
Primary completion
Oct 18, 2030
Study completion Oct 3, 2033
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Nov 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity. The main purpose of the study is to evaluate if the combination of Elranatamab, Daratumumab and Lenalidomide offers superior clinical benefit compared with the combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in people with newly diagnosed multiple myeloma. There are 2 parts to this study. Part 1 will characterize the safety and tolerability of elranatamab in combination with daratumumab and lenalidomide or in combination with lenalidomide and will identify the optimal dose(s) of the combination regimen. Part 2 of the study will evaluate the rate of minimal residual disease (MRD) negative CR and the progression free survival (PFS) of the combination of elranatamab, daratumumab, and lenalidomide compared with the combination of daratumumab, bortezomib, lenalidomide, and dexamethasone in participants with newly diagnosed multiple myeloma.
Conditions
- Multiple Myeloma
Interventions
ElranatamabDrug
Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
DaratumumabDrug
Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
LenalidomideDrug
Part 1 Dose Level 1 is not randomized. All other cohorts are randomized.
DexamethasoneDrug
Randomized
BortezomibDrug
Randomized
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 Dose Limiting ToxicityTime frame: From the first dose of elranatamab/first full dose in combination with EDR until 28 days (+/- visit window) from the first administration of elranatamab with daratumumab and lenalidomide
- Part 2: Progression free survival per IMWGTime frame: From randomization up to 97 months.
- Part 2: Minimal Residual Disease negative CR rateTime frame: At 12 months after randomization
Locations
180 sites in 25 countries. Site status is shown where the registry gives one.
Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Malbis
Daphne, Alabama · Recruiting
Gulf Health Hospitals, Inc. d/b/a Thomas Medical Center
Daphne, Alabama · Recruiting
Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Fairhope
Fairhope, Alabama · Recruiting
Mobile Infirmary Association d/b/a Mobile Infirmary Medical Center
Mobile, Alabama · Recruiting
Gulf Health Hospitals, Inc. d/b/a Infirmary Cancer Care - Mobile
Mobile, Alabama · Recruiting
Mobile Infirmary Medical Center
Mobile, Alabama · Recruiting
Mobile Infirmary Association d/b/a Mobile Infirmary Medical Center.
Mobile, Alabama · Recruiting
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center
Coral Gables, Florida · Recruiting
Sylvester Comprehensive Cancer Center - Coral Springs
Coral Springs, Florida · Recruiting
University of Miami Hospital and Clinics Deerfield Beach
Deerfield Beach, Florida · Recruiting
Sylvester Comprehensive Cancer Center- Doral
Doral, Florida · Recruiting
Sylvester Comprehensive Cancer Center - Hollywood
Hollywood, Florida · Recruiting
Jupiter Medical Center/Anderson Family Cancer Institute
Jupiter, Florida · Recruiting
Sylvester Comprehensive Cancer Center
Miami, Florida · Recruiting
University of Miami Hospital and Clinics
Miami, Florida · Recruiting
Sylvester Comprehensive Cancer Center Kendall
Miami, Florida · Recruiting
Sylvester Comprehensive Cancer Center - Sole Mia
North Miami, Florida · Recruiting
Sylvester Comprehensive Cancer Center - Plantation
Plantation, Florida · Recruiting
NHO Revive Research Institute, LLC
Lincoln, Nebraska · Recruiting
Renown Health Medical Oncology
Reno, Nevada · Recruiting
Renown Office of Clinical Research
Reno, Nevada · Recruiting
Renown Regional Medical Center
Reno, Nevada · Recruiting
MSK Basking Ridge
Basking Ridge, New Jersey · Recruiting
MSK Monmouth
Middletown, New Jersey · Recruiting
MSK Bergen
Montvale, New Jersey · Recruiting
MSK Commack
Commack, New York · Recruiting
MSK Westchester
Harrison, New York · Recruiting
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, New York · Recruiting
Memorial Sloan Kettering Cancer Center-Main Campus
New York, New York · Recruiting
MSK Nassau
Uniondale, New York · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
LDS Hospital
Salt Lake City, Utah · Recruiting
Intermountain Cancer Center St. George
St. George, Utah · Recruiting
St. George Regional Hospital
St. George, Utah · Recruiting
Hospital Privado Universitario de Córdoba
Córdoba, Córdoba Province, Argentina · Not yet recruiting
Sanatorio de La Mujer
Rosario, Santa Fe Province, Argentina · Not yet recruiting
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia · Recruiting
Pindara Private Hospital
Benowa, Queensland, Australia · Recruiting
St Vincent's Hospital Melbourne
Fitzroy, Victoria, Australia · Recruiting
Epworth Freemasons
Melbourne, Victoria, Australia · Recruiting
Showing 40 of 180 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.